INVU (song)

Engine Biosciences Secures $27 Million Series A Extension to Advance Development of Precision Oncology Medicines and Novel Biomarkers for Patient Selection

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Oncology, Health Technology, Research, Genetics, Science, Finance, Neoplasm, Polaris Partners, MIT, Enterprise Singapore, UCSF, Silicon, Biomarker, Therapy, Economics, UCSD, Liver, Amaravati seed capital road, INVU (song), Drug development, Enterprise, Temasek, Lung, Growth, PKMYT1, Medicine, Biology, Machine learning, SEEDS, Doctor of Philosophy, Mayo Clinic, Medical imaging, Pharmaceutical industry, Engine

Engine Biosciences , a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, today announced the completion of a $27 million Series A extension.

Key Points: 
  • Engine Biosciences , a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, today announced the completion of a $27 million Series A extension.
  • Engine’s precision medicine R&D platform deciphers biological networks and pinpoints key genetic interactions driving diseases, overcoming challenges presented by biological complexity.
  • These insights reveal targets and therapeutics to be used in biomarker-defined patient populations, allowing for more rapid identification of effective precision medicines.
  • In addition to high-value targets and drug candidates, Engine identified new patient selection biomarkers for several distinct classes of targeted therapies.

Portfolio company Harpoon Therapeutics announces up to $150 million private placement

Retrieved on: 
Thursday, October 26, 2023
Harpoon, Biotechnology, INVU (song), LSE, PIPE, Security (finance), Citadel

Arix’s holding value will continue to be determined by the market price of Harpoon’s shares.

Key Points: 
  • Arix’s holding value will continue to be determined by the market price of Harpoon’s shares.
  • Harpoon intends to use the net proceeds to fund its clinical development programs from its platforms, including ongoing as well as future late-stage clinical studies of HPN328.
  • Robert Lyne, CEO of Arix, stated: “Following the announcement of strong data sets across Harpoon’s best-in-class immunotherapy pipeline, we welcome this private placement alongside the addition of quality new investors on the register.
  • This placement represents an additional vote of confidence by these new and existing investors, further underpinning Harpoon with a strong cash runway going into 2026.”
    The full text from Harpoon’s announcement is reproduced below, and can be accessed on Harpoon Therapeutics’ website at: www.harpoontx.com .

Harpoon Therapeutics Announces Up to $150 Million Private Placement

Retrieved on: 
Monday, October 23, 2023
Sale, INVU (song), TD, PIPE, Therapy, SAN, Security (finance), Citadel

Each full warrant will represent the right to purchase one share of the Company’s common stock at an exercise price of $5.8345 per share.

Key Points: 
  • Each full warrant will represent the right to purchase one share of the Company’s common stock at an exercise price of $5.8345 per share.
  • The accompanying warrants will be exercisable upon issuance for a period of three years following the date of issuance.
  • TD Cowen is acting as the lead placement agent for the PIPE financing.
  • Canaccord Genuity and H.C. Wainwright & Co. are also acting as placement agents for the PIPE financing.

Health Data Analytics Institute (HDAI) Announces $31 Million Funding Round to Scale Predictive Risk Platform

Retrieved on: 
Monday, October 2, 2023
Cleveland Clinic, Population health, Health, Case management (US healthcare system), EVP, Synthetic media, INVU (song), History, Acos, Patient, Physician, Machine learning, Generative, Artificial intelligence, AI, Chamoun, Scale, Dana–Farber Cancer Institute, Medical device, Houston Methodist Hospital

BOSTON, Oct. 2, 2023 /PRNewswire/ -- Health Data Analytics Institute (HDAI)— an artificial intelligence (AI) company focused on empowering clinicians, optimizing care pathways, and improving patient outcomes — today announced an oversubscribed Series C financing to scale its predictive risk platform.

Key Points: 
  • Several preeminent health systems including Houston Methodist, Cleveland Clinic, and Dana-Farber Cancer Institute, are collaborating with HDAI on various initiatives.
  • HDAI has additional collaborations with over 40 Medicare Accountable Care Organizations (ACOs) through which it collectively generates 50 million weekly predictions for one million patients.
  • The platform forecasts health risk at patient, practice, institution and/or regional levels and supports clinicians and institutions in driving performance improvements.
  • Health Data Analytics Institute (HDAI) is a care optimization, decision support and provider enablement company powered by big data, AI-powered analytics, expert insights and point of care technology solutions.

PayJoy Announces $360M in Funding to Support Growth

Retrieved on: 
Tuesday, September 5, 2023
Union Square Ventures, Warburg Pincus, Citigroup, Multimedia, SAN, Citibank, Bank, INVU (song)

The equity was led by Warburg Pincus, with participation from Invus, Citi Ventures and prior leads Union Square Ventures and Greylock.

Key Points: 
  • The equity was led by Warburg Pincus, with participation from Invus, Citi Ventures and prior leads Union Square Ventures and Greylock.
  • The debt funding was led by Citi and includes other institutional investors as well as PayJoy's own in-house fund.
  • "I am extremely grateful to our partners on both the equity and debt side who support our mission," said Doug Ricket, PayJoy co-founder and CEO.
  • "Despite a challenging  environment over the past year, PayJoy has been able to grow and expand.

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Retrieved on: 
Monday, July 31, 2023
GMP, CYCN, Central nervous system, INVU (song), Biomarker, Doctor of Philosophy, CNS, Leverage, Sale, Accelerated approval (FDA), CGMP, Patient, Therapy, Rare, Security (finance), Pharmaceutical industry, MELAS, Polaris, Venrock

CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement. Tisento is launching with an $81 million Series A financing to support its development of the Phase 2 soluble guanylate cyclase (sGC) stimulator zagociguat in MELAS and other genetic mitochondrial diseases, as well as the company’s advancement of additional assets for serious diseases with unmet need.

Key Points: 
  • Phase 2a clinical data, generated by Cyclerion, showed rapid improvements in disease-associated biomarkers in patients with MELAS who received zagociguat for 28 days.
  • Cyclerion received 10 percent equity ownership in Tisento with anti-dilution protection through $100 million in post-money valuation, as well as the right to purchase additional Tisento equity in the future.
  • The Tisento equity ownership provides Cyclerion shareholders with the opportunity to benefit from future Tisento value creation without further financial or operational obligations for the Tisento assets.
  • The launch of Tisento supports the optimal advancement of zagociguat and CY3018 while providing Cyclerion with near-term capital and potential future value for our shareholders.

Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

Retrieved on: 
Monday, June 5, 2023
Exercise, Attention, Telephone, Jefferies, Enterprise file synchronization and sharing, Research, Sale, Prospectus, Jefferies Group, Investment, TEL, Form, Madison Avenue, Nicollet Mall, United, Lexicon, Security (finance), INVU (song), Citigroup

THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock.

Key Points: 
  • THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock.
  • The closing included the issuance and sale of an additional 3,588,705 shares of common stock to the underwriters pursuant to the full exercise of their option to purchase additional shares.
  • After giving effect to the full exercise of the underwriters’ option to purchase additional shares, the total number of shares of common stock sold in the public offering was 27,513,410, and total gross proceeds from the public offering were approximately $71.5 million, before deducting underwriting discounts and commissions and other offering expenses.
  • An affiliate of Invus, L.P., Lexicon’s largest shareholder, also exercised in full its option to purchase an additional 3,622,832 shares of common stock in connection with the concurrent private placement.

Lexicon Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, May 31, 2023
Exercise, Attention, Telephone, Jefferies, Enterprise file synchronization and sharing, Research, Securities and Exchange Commission (Nigeria), Sale, Prospectus, Jefferies Group, Investment, Form S-3, TEL, Form, Madison Avenue, Nicollet Mall, Lexicon Pharmaceuticals, Lexicon, Life insurance, Security (finance), INVU (song), Citigroup

THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001.

Key Points: 
  • THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001.
  • In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock.
  • There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
  • Lexicon intends to grant the private placement purchaser an option to purchase, on a pro rata basis, additional shares of common stock to the extent the underwriters exercise their option to purchase additional common stock.

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Retrieved on: 
Thursday, May 11, 2023
LLP, MELAS, CYCN, Stifel, Technology Development Board, INVU (song), Venrock, CNS, Patient, Therapy, Security (finance), NewCo

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) announced today that it has signed a definitive agreement with a new private company (“NewCo”) to sell two of its sGC stimulator assets in exchange for cash and equity ownership. Investors in NewCo have agreed to invest $81M to develop zagociguat (previously CY6463) to treat MELAS* and other diseases associated with mitochondrial dysfunction and advance CY3018.

Key Points: 
  • Investors in NewCo have agreed to invest $81M to develop zagociguat (previously CY6463) to treat MELAS* and other diseases associated with mitochondrial dysfunction and advance CY3018.
  • Each of the current Cyclerion investors who are participating in the NewCo capitalization have agreed to vote their Cyclerion shares in favor of the transaction.
  • Following the closing, NewCo will be solely responsible for all activities and expenses related to developing and commercializing zagociguat and CY3018.
  • Signing of the definitive agreement triggered the previously announced $5M equity investment by CEO Peter Hecht.

Noema Pharma to Present at BioEquity Europe 2023

Retrieved on: 
Tuesday, May 9, 2023
Senior management, INVU (song), Outline, Polaris Partners, Noema, USD, CNS, Sofinnova

BASEL, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members of its Management Team will present at BioEquity Europe taking place May 14-16, 2023, in Dublin, Ireland.

Key Points: 
  • BASEL, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members of its Management Team will present at BioEquity Europe taking place May 14-16, 2023, in Dublin, Ireland.
  • Noema management will provide an update on its clinical development activities and outline anticipated milestones.
  • For scheduling a meeting with the Noema Pharma management team, please contact [email protected] .
  • UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus to complete the round.